AIM
NKTR icon

Alambic Investment Management’s Nektar Therapeutics NKTR Stock Holding History

Alambic Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-692
Closed -$633K – 356
2018
Q3 		$633K Sell
692
-122
-15% -$104K 0.5% 67
2018
Q2 		$597K Sell
814
-1,899
-70% -$2.19M 0.16% 190
2018
Q1 		$4.33M Buy
2,713
+744
+38% +$959K 0.6% 29
2017
Q4 		$1.76M Buy
+1,969
New +$1.16M 0.21% 165
2017
Q3 		– Sell
-1,020
Closed -$299K – 556
2017
Q2 		$299K Sell
1,020
-980
-49% -$283K 0.04% 455
2017
Q1 		$704K Buy
2,000
+727
+57% +$163K 0.09% 335
2016
Q4 		$234K Buy
+1,273
New +$259K 0.04% 472

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alambic Investment Management's NKTR Position: Q4 2018 in Review

Alambic Investment Management sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 692 shares — an estimated $633K sold.

Alambic Investment Management first reported a position in NKTR in Q4 2016 and held it in 7 quarters. The position peaked at $4.33M in Q1 2018. 343 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

  • Alambic Investment Management reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Alambic Investment Management sold 692 Nektar Therapeutics shares in Q4 2018, an estimated $633K.
  • Alambic Investment Management first reported a position in Nektar Therapeutics in Q4 2016 and held it in 7 quarters.
  • Alambic Investment Management's Nektar Therapeutics position peaked at $4.33M in Q1 2018.
  • 343 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Alambic Investment Management's 13F filing for Q4 2018, filed 12 Feb 2019.